Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling ...
Day One Biopharmaceuticals, Inc., headquartered in Brisbane, California, is a clinical-stage biopharmaceutical organization dedicated to the discovery and commercialization of precise therapeutic interventions for patients suffering from genetically defined cancers. Since its inception in 2018, the company has prioritized high-unmet-need areas, specifically pediatric oncology, where traditional drug development pipelines have ...Day One Biopharmaceuticals, Inc., headquartered in Brisbane, California, is a clinical-stage biopharmaceutical organization dedicated to the discovery and commercialization of precise therapeutic interventions for patients suffering from genetically defined cancers. Since its inception in 2018, the company has prioritized high-unmet-need areas, specifically pediatric oncology, where traditional drug development pipelines have historically been sparse.
The company’s lead therapeutic asset, tovorafenib (DAY101), is an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. This drug has been the focal point of their clinical efforts, particularly for young patients battling recurrent or progressive low-grade glioma. Beyond its lead asset, the company maintains a pipeline focused on first- or best-in-class oncology medicines, such as Pimasertib, an oral small molecule inhibitor of MEK1/2, aimed at expanding its portfolio of targeted therapies.
Financially, Day One operates as a growth-stage biotech with a significant focus on R&D, which historically consumes the vast majority of its revenue—a standard trajectory for clinical-stage firms. The company’s financial health is underpinned by a strong current ratio and substantial cash reserves, positioning it to sustain its research and operational objectives. As of the latest reporting, the enterprise maintains an lean, agile organizational structure with approximately 178 full-time employees, emphasizing high expertise in oncology and drug development. Key leadership, including CEO Jeremy Bender, guides the firm's strategic direction to navigate the complex regulatory landscapes of the FDA. The company, which went public in May 2021 (NASDAQ: DAWN), continues to bridge the gap between bench research and patient access. While the firm deals with typical biotech risks, including cash-flow volatility and the challenges of late-stage clinical trials, its strategic focus on genetically defined cancers—which often allows for more efficient trial designs—remains a cornerstone of its competitive advantage in the healthcare sector. The recent integration into the broader oncology landscape, coupled with its focus on pediatric needs, positions Day One as a critical player in precision medicine.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$158.2M
+20.6%
+35.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-107.3M
-12.4%
-7.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+89.1%
-7.1%
-0.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-80.8%
+51.2%
+16.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-67.8%
+6.8%
+20.1%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-104.1M
-29.6%
-204.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-65.8%
-7.5%
-125.2%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.6%
+22.3%
-1.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
8.02x
+4.7%
-7.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Hello, ladies and gentlemen. Welcome to the Day One Biopharmaceuticals, Inc. Fourth Quarter and Full Year 2025 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Please be advised that this conference call is being recorded. I would now like to turn the call over to Joey Perrone, Senior Vice President of Finance and Investor Relations. Please go ahead.
Joey Perrone: Thank you. Hello, everyone, and good afternoon. Welcome to Day One Biopharmaceuticals, Inc.'s fourth quarter and full year 2025 financial and operating results conference call. Earlier today, we issued a press release that outlines the topics we plan to discuss today. You can access the press release and the slides to accompany this conference call in the Investors and Media section of our website at www.dayonebio.com. An audio webcast with the corresponding slides is also available on the website. Before we get started, I would like to remind everyone that some of the statements that we make on this call and information presented in the slide deck include forward-looking statements as outlined on Slide 2. Actual events or results could differ materially from those expressed or implied by any forward-looking statements. We encourage you to review the various risks, uncertainties, and other factors included in our most recent filings with the SEC and any other future filings that we may make with the SEC. These forward-looking statements are based on our current estimates and various assumptions and reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products and product candidates, operating plans, and performance. You are cautioned not to place any undue reliance on these forward-looking statements and, except as required by law, Day One Biopharmaceuticals, Inc. disclaims any obligation to update such statements. Today, I am joined by Dr. Jeremy Bender, Chief Executive Officer; Lauren Merendino, Chief Commercial Officer; Charles York, Chief Operating and Financial Officer; and Dr. Michael Vasconcelles, Head of Research and Development. I will now turn the call over to Jeremy.
Jeremy Bender: Thank you, Joey. Good afternoon, and thank you for joining us. We are proud to present today our fourth quarter earnings and full year financial results for 2025. 2025 was our first full year as a commercial company. With the launch and uptake of Ojemda in pediatric low-grade glioma, we have now demonstrated we can deliver on our mission to develop new medicines for people of all ages with life-threatening diseases. Importantly, we have also now taken the initial steps needed to repeat this with meaningful pipeline advancements. Together, the Day One Biopharmaceuticals, Inc. team achieved seminal commercial and clinical milestones in 2025 that have positioned us for accelerated growth in 2026. Ojemda continues to be the primary revenue and growth driver for the company. …
